ITA ENG HOME WHO WE ARE THERAPEUTIC AREAS INNOVATION & RESEARCH WORK WITH US ETHICS AND COMPLIANCE PHARMACOVIGILANCE AREA GASTROENTEROLOGICAL ULCER The ulcer, localized to the stomach or duodenum, is the consequence of an inflammatory / erosive process affecting the mucous membrane of these organs. It is an acid-related disease and is manifested by pain and heartburn. In recent years it has been shown that in many cases of gastric and duodenal ulcer there is inflammation of the stomach due to a germ called Helicobacter pylori, a bacterium that can resist stomach acid, whose role in ulcer, as well as in other important digestive diseases, it was clarified at the end of the last century. The eradication of Helicobacter pylori at the gastroduodenal level generally determines the disappearance of the ulcer disease, preventing its recurrence. The most widespread and most rational therapy, according to modern scientific findings, provides for the GASTROESOPHAGEOUS REFLUX DISEASE It is estimated that 10-20% of the general population suffers from gastroesophageal reflux disease (GERD) caused by gastroesophageal reflux (GER). We speak of "disease" (GERD) when reflux causes symptoms such as intense burning, localized behind the breastbone (retro-sternal heartburn), often accentuated by the flexion of the bust and accompanied by pain and acid regurgitation. At other times the disease has atypical (extradigestive) symptoms and manifests itself for example with cough and hoarseness. It is caused by the abnormal and persistent passage of acid from the stomach into the esophagus (reflux esophagitis). The esophageal mucosa is particularly sensitive to acid and when the frequency and intensity of reflux takes on a pathological value over time the inflammation can evolve into irreversible damage to the esophagus, in the form of erosions and small ulcers and the development of precancerous lesions (esophagus by Barrett). ULCERATIVE RECTOCULITIS Ulcerative colitis is a chronic inflammatory disease that primarily affects the rectum and can involve part or all of the colon. The causes of this inflammation are still unknown. The main clinical symptoms are diarrhea, often with blood and mucus, and abdominal pain. Up to 35% of cases may have extra-intestinal symptoms, such as joint pain and dermatological manifestations. The disease is characterized by acute episodes followed by periods of remission in which it is clinically silent. The frequency of symptomatic episodes can range from one or two attacks per year to numerous episodes that reduce the period of well-being. If not well treated, chronic inflammation can lead over time to irreversible changes in intestinal cells with the possible development of cancerous lesions. For this reason, and to avoid exacerbations, therapy is also taken during periods of well-being. THE IRRITABLE INTESTINAL SYNDROME This is a "functional" disease, ie an alteration in the functioning of the intestine and affects women more frequently than men. It manifests itself with abdominal pain and swelling, changes in defecation (constipation, diarrhea or alternation of the two). The pain can be continuous or recurrent (colic) and has variable intensity. Often in the same person, pain can take on different characteristics, also in relation to precipitating factors (type of diet, state of anxiety, stress, etc.). Harrison. Principles of internal medicine. 16th edition. PHARMACOVIGILANCE Pharmacovigilance: what does it mean to monitor a drug? FARMINDUSTRIA Linee Guida per l'Informazione Scientifica ETICA E COMPLIANCE Siamo convinti che porre integrità ed etica nel nostro agire, sia la nostra forza e la chiave per un sempre maggior successo. CHI SIAMO Storia I Valori e la Mission Contattaci Privacy Preferenze cookie AREE TERAPEUTICHE Area Allergologica Area Antibiotica Area Cardiovascolare Area Dolore Area Gastroenterologica Area Respiratoria Area Urologica I nostri prodotti INNOVAZIONE & RICERCA LAVORA CON NOI Posizioni aperte Invia il tuo curriculum FARMACOVIGILANZA MALESCI Istituto Farmacobiologico S.p.A. - Sede Legale: Bagno a Ripoli – Via Lungo l’Ema, 7– 50012 Bagno a Ripoli(Fi) Tel. 05564941 - Fax 055/645599 - Codice Fiscale e Partita IVA: 00408570489 - Numero di iscrizione registro imprese: FI-55452 - Capitale I.V.: € 255.000 - Società soggetta all'attività di direzione e coordinamento di A. Menarini Industrie Farmaceutiche Riunite S.r.l. Copyright 2021 Malesci ITALY - Tutti i diritti riservati - P.Iva: 00408570489 Our site uses cookies. If you close the banner BY CLICKING ON THE X, only technical cookies will be installed on your device, ie "strictly necessary" cookies (without which the site would not work), as well as, where present, "performance cookies", which perform aggregate statistics on use of the site. On the contrary, all other categories of cookies that may be present on the site, ie "functional cookies", which allow better navigation usability (eg, remembering the settings selected by the user during previous visits to the site), the "cookies of targeted advertising "and" social media "cookies, which allow you to submit content, including advertising, in line with the preferences expressed by you in the context of surfing the net on this and other sites, automatically detected (profiling), they will be installed only by clicking "ACCEPT". If you want to know more click on COOKIE POLICY. To view the list of cookies actually present on the site, customize the types of cookies desired and third parties who could access the data, click on "ADDITIONAL INFORMATION". I ACCEPT ADDITIONAL INFORMATION